NZ272142A - 1,2-disubstituted amine-2-ethyl intermediates - Google Patents

1,2-disubstituted amine-2-ethyl intermediates

Info

Publication number
NZ272142A
NZ272142A NZ272142A NZ27214294A NZ272142A NZ 272142 A NZ272142 A NZ 272142A NZ 272142 A NZ272142 A NZ 272142A NZ 27214294 A NZ27214294 A NZ 27214294A NZ 272142 A NZ272142 A NZ 272142A
Authority
NZ
New Zealand
Prior art keywords
compound
prepared
mixture
nmr
ppm
Prior art date
Application number
NZ272142A
Other languages
English (en)
Inventor
Masayuki Matsukura
Keizo Sato
Naoki Yoneda
Makoto Kaino
Kazutoshi Miyake
Yoshiharu Daiku
Naoya Kishi
Fusayo Yoshida
Kenichi Nomoto
Toshiaki Ogawa
Tadanobu Takamura
Koichi Nose
Mikio Tomimatsu
Masanori Mizuno
Shigeto Negi
Shigeru Souda
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NZ272142A publication Critical patent/NZ272142A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
NZ272142A 1993-06-24 1994-06-22 1,2-disubstituted amine-2-ethyl intermediates NZ272142A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP17727893 1993-06-24
JP20290393 1993-07-23
JP22792493 1993-08-21
JP23718893 1993-08-31
NZ260816A NZ260816A (en) 1993-06-24 1994-06-22 N-substituted,2-substituted-2-propen(thio)amide; 4-pyrazolyl-, 4-imidazolyl-propenoic acid intermediates

Publications (1)

Publication Number Publication Date
NZ272142A true NZ272142A (en) 1996-11-26

Family

ID=27474760

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ272142A NZ272142A (en) 1993-06-24 1994-06-22 1,2-disubstituted amine-2-ethyl intermediates
NZ260816A NZ260816A (en) 1993-06-24 1994-06-22 N-substituted,2-substituted-2-propen(thio)amide; 4-pyrazolyl-, 4-imidazolyl-propenoic acid intermediates

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ260816A NZ260816A (en) 1993-06-24 1994-06-22 N-substituted,2-substituted-2-propen(thio)amide; 4-pyrazolyl-, 4-imidazolyl-propenoic acid intermediates

Country Status (12)

Country Link
US (2) US5541213A (enExample)
EP (1) EP0630894A1 (enExample)
JP (1) JP3815691B2 (enExample)
KR (1) KR950000693A (enExample)
CN (1) CN1111622A (enExample)
AU (1) AU683460B2 (enExample)
CA (1) CA2126020A1 (enExample)
FI (1) FI942923A7 (enExample)
HU (1) HUT71106A (enExample)
NO (1) NO942372L (enExample)
NZ (2) NZ272142A (enExample)
TW (1) TW278074B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
WO1997004774A1 (en) * 1995-08-02 1997-02-13 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1997026246A1 (en) * 1996-01-16 1997-07-24 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
WO1997028159A1 (en) * 1996-02-01 1997-08-07 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0885217A4 (en) * 1996-02-01 1999-04-21 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
ID18983A (id) * 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
US20060211731A1 (en) * 1999-05-05 2006-09-21 Les Laboratories Servier New substituted pyridine or piperidine compounds
AU2003211385A1 (en) 2002-02-28 2003-09-09 Takeda Chemical Industries, Ltd. Azole compounds
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US7423159B2 (en) 2002-11-01 2008-09-09 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
DE10300124A1 (de) * 2003-01-07 2004-07-15 Bayer Ag Verfahren zur Herstellung von Arylalkinen
WO2008010511A1 (en) * 2006-07-19 2008-01-24 Takeda Pharmaceutical Company Limited Screening method
EP1939180A1 (en) * 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
DE102008039083A1 (de) * 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) * 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
WO2012177782A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
CN117229268A (zh) 2011-07-29 2023-12-15 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
KR102022715B1 (ko) * 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
JP6195909B2 (ja) 2012-05-09 2017-09-13 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
BR112015032071B1 (pt) 2013-06-21 2022-06-14 Karyopharm Therapeutics Inc Modulares do transporte nuclear e suas utilizações
AU2015301484B2 (en) 2014-08-15 2020-02-20 Karyopharm Therapeutics Inc. Polymorphs of selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
CN111943900B (zh) * 2019-05-17 2023-11-17 宁夏苏融达化工有限公司 异噁唑啉衍生物及其在农业中的应用
WO2024125464A1 (en) * 2022-12-11 2024-06-20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Tetrahydroisoquinolin-one derivatives, preparation methods and medicinal uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3542661A1 (de) * 1985-12-03 1987-06-04 Bayer Ag Imidazopyridazinalkensaeureamide, verfahren zu ihrer herstellung, zwischenprodukte zu ihrer herstellung
US4743238A (en) * 1986-03-17 1988-05-10 Malcolm Nicol & Co. Wetness indicating hot-melt adhesives
US4769466A (en) * 1987-02-06 1988-09-06 Pennwalt Corporation 2-aminoacetamide pyridinyl derivatives
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
ATE211384T1 (de) * 1991-01-29 2002-01-15 Fujisawa Pharmaceutical Co Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof

Also Published As

Publication number Publication date
NZ260816A (en) 1996-11-26
CA2126020A1 (en) 1994-12-25
JPH07118237A (ja) 1995-05-09
US5606073A (en) 1997-02-25
FI942923A7 (fi) 1994-12-25
HU9401917D0 (en) 1994-09-28
AU6487894A (en) 1995-01-05
FI942923A0 (fi) 1994-06-17
TW278074B (enExample) 1996-06-11
EP0630894A1 (en) 1994-12-28
CN1111622A (zh) 1995-11-15
NO942372D0 (enExample) 1994-06-22
AU683460B2 (en) 1997-11-13
JP3815691B2 (ja) 2006-08-30
NO942372L (no) 1994-12-27
HUT71106A (en) 1995-11-28
US5541213A (en) 1996-07-30
KR950000693A (ko) 1995-01-03

Similar Documents

Publication Publication Date Title
NZ272142A (en) 1,2-disubstituted amine-2-ethyl intermediates
EP0254322B1 (en) Benzimidazole derivatives
US5141950A (en) Benzimidazole compounds and their use
CA2264798A1 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
JPH0764841B2 (ja) インドール誘導体およびその用途
CA2696429A1 (en) Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
CA1337202C (en) Cyclic amides which are leukotriene antagonists
JPH02152966A (ja) ４−ヒドロキシカルボスチリル誘導体
JPS6277375A (ja) Ｎ―置換２―アミノチアゾール類及び治療用組成物
JPS6363661A (ja) ジヒドロピリジン抗アレルギ−および抗炎症剤
JPH0717589B2 (ja) 新規１，３―ジカルボニル化合物およびその組成物
KR900006118B1 (ko) 4-퀴놀론 유도체의 제법
JPH08508031A (ja) ５‐ｈｔ１ａリガンドとしてのアミド誘導体
JPH05262761A (ja) アリールアルキルアミン誘導体
JPH08501287A (ja) アミド誘導体
JPH0377867A (ja) 新規オキサゾロピリジン誘導体
JPH05194403A (ja) 複素環置換されたキノリルメトキシ−フエニルアセトアミド
JPH07503002A (ja) Ｎｍｄａアンタゴニストとしてのニトロキノロン誘導体
US5356922A (en) Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
GB2126230A (en) Substituted 1-pyridyloxy-3- indolylakylamino-2-propanols, preparation, and use thereof
JPS5976083A (ja) ジヒドロピリジン類
JPH04288073A (ja) ピペラジン誘導体
JP2002511451A (ja) アザシクロアルカン誘導体、その製造及び治療上の使用
JP2905219B2 (ja) ブテン酸誘導体
IE67059B1 (en) A process for the preparation of a 1,4-dihydropyridine derivative namely (-)-2-{[2-(aminoethoxy)ethoxy]methyl}-4-(2,3-dichlorophenyl)-3-ethoxy-carbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine and its salts